Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel

Abstract

Aim: Chemoresistance is a prevalent issue in cancer treatment. Paclitaxel (PTX) is a microtubule-binding anticancer drug used in various cancer treatments. However, cancer cells often show chemoresistance against PTX with the help of P-glycoprotein (Pgp) - a drug efflux pump. It has also been observed that overexpressed T-type calcium channels (TTCCs) maintain calcium homeostasis in cancer cells, and calcium has a role in chemoresistance. Therefore, the aim of this study was to test the adjuvant role of TTA-A2, a TTCC blocker, in enhancing the anticancer effect of PTX on the A549 lung adenocarcinoma cell line.

Methods: Morphology assay, calcium imaging assay, clonogenic assay, apoptosis assay, and real-time polymerase chain reaction (real-time PCR) were performed to find the adjuvant role of TTA-A2. Samples were treated with PTX at 10 nM concentration and TTA-A2 at 50 and 100 nM concentrations. PTX and TTA-A2 were used in the combination treatment at 10 and 100 nM concentrations, respectively.

Results: Immunocytochemistry confirmed the expression of TTCC in A549 cells. Morphology assay showed altered morphology of A549 cells. The adjuvant role of TTA-A2 was observed in the calcium imaging assay in spheroids, in the clonogenic assay in monolayers, and in the apoptosis assay in both cultures. With real-time PCR, it was observed that, even though cells express the mRNA of Pgp, it is non-significant upon treatment with PTX and TTA-A2.

Conclusion: TTA-A2 can be used as an adjuvant to reduce chemoresistance in cancer cells as well as to enhance the anticancer effect of the standard anticancer drug PTX. Being a potent TTCC inhibitor, TTA-A2 may also enhance the anticancer effects of other anticancer drugs.

Keywords

TTA-A2 / paclitaxel / adjuvant / lung adenocarcinoma / T-type calcium channel blocker

References

[1] Global cancer cases reach 14 million, World Health Organization says, BBC News. (2013). Available from: https://www.bbc.com/news/health-25346639 [Last accessed on 11 Nov 2021]

[2] Worldwide cancer statistics, Cancer Res. UK. (2015). Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer [Last accessed on 11 Nov 2021]

[3] Boehmerle W,Sivula M.Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation.Proc Natl Acad Sci U S A2007;104:11103-8 PMCID:PMC1904151

[4] Weaver BA.How Taxol/paclitaxel kills cancer cells.Mol Biol Cell2014;25:2677-81 PMCID:PMC4161504

[5] Priyadarshini K.Paclitaxel against cancer: a short review.Med chem2012;2:139-41

[6] Mekhail TM.Paclitaxel in cancer therapy.Expert Opin Pharmacother2002;3:755-66

[7] Ramalingam S.Paclitaxel for non-small cell lung cancer.Expert Opin Pharmacother2004;5:1771-80

[8] Ghamande S,Marchetti D,Odunsi K.Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer.Int J Gynecol Cancer2003;13:142-7

[9] Perez EA.Paclitaxel in breast cancer.Oncologist1998;3:373-89

[10] Obasaju C.Paclitaxel and docetaxel in prostate cancer.Hematol Oncol Clin North Am2001;15:525-45

[11] Glass-Marmor L.Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP.Eur J Pharmacol1999;370:195-9

[12] Zhao M,Yang Y.Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp.PLoS One2015;10:e0131429-e PMCID:PMC4504487

[13] Orr GA,McDaid H.Mechanisms of Taxol resistance related to microtubules.Oncogene2003;22:7280-95 PMCID:PMC4039039

[14] Yang H,He J.Regulation of calcium signaling in lung cancer.J Thorac Dis2010;2:52-6 PMCID:PMC3256429

[15] Büsselberg D.Targeting intracellular calcium signaling ([Ca²⁺]_i) to overcome acquired multidrug resistance of cancer cells: a mini-overview.Cancers2017;9:48 PMCID:PMC5447958

[16] Cui C,Fu L.Targeting calcium signaling in cancer therapy.Acta Pharm Sin B2017;7:3-17 PMCID:PMC5237760

[17] Rossier MF.T-type calcium channel: a privileged gate for calcium entry and control of adrenal steroidogenesis.Front Endocrinol2016;7:43 PMCID:PMC4873500

[18] Monteith GR,Roberts-Thomson SJ.Calcium channels and pumps in cancer: changes and consequences.J Biol Chem2012;287:31666-73 PMCID:PMC3442501

[19] Tajada S.Calcium permeable channels in cancer hallmarks.Front Pharmacol2020;11:968 PMCID:PMC7358640

[20] Taylor JT,Pottle JE.Calcium signaling and T-type calcium channels in cancer cell cycling.World J Gastroenterol2008;14:4984-91 PMCID:PMC2742923

[21] Antal L.T-type calcium channels in cancer.Cancers (Basel)2019;11:134 PMCID:PMC6407089

[22] Kumari N,Bhargava A.Cardiac voltage gated calcium channels and their regulation by β-adrenergic signaling.Life Sci2018;194:139-49

[23] Wang CY,Phan NN,Lin YC.Meta-analysis of public microarray datasets reveals voltage-gated calcium gene signatures in clinical cancer patients.PLoS One2015;10:e0125766 PMCID:PMC4493072

[24] Valerie NC,Hosing AS.Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells.Biochem Pharmacol2013;85:888-97

[25] Dziegielewska B,Yang WZ,Dziegielewski J.T-type Ca²⁺ channel inhibition sensitizes ovarian cancer to carboplatin.Mol Cancer Ther2016;15:460-70 PMCID:PMC4783280

[26] Kraus RL,Gregan Y.In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice.J Pharmacol Exp Ther2010;335:409-17

[27] Kumari N,Rath SN.T-type calcium channel antagonist, TTA-A2 exhibits anti-cancer properties in 3D spheroids of A549, a lung adenocarcinoma cell line.Life Sci2020;260:118291

[28] Schindelin J,Frise E.Fiji: an open-source platform for biological-image analysis.Nat Methods2012;9:676-82 PMCID:PMC3855844

[29] Schneider CA,Eliceiri KW.NIH Image to ImageJ: 25 years of image analysis.Nat Methods2012;9:671-5 PMCID:PMC5554542

[30] V S S.Degradation of Poly(ε-caprolactone) and bio-interactions with mouse bone marrow mesenchymal stem cells.Colloids Surf B Biointerfaces2018;163:107-18

[31] Origin(Pro), OriginLab Cooperation, Northampton, MA, USA. Available from: https://www.originlab.com/index.aspx?go=Company&pid=1130 [Last accessed on 11 Nov 2021]

[32] Tram N,Bellucci L.Intracellular concentrations of Fura-2 and Fura-2/AM in vascular smooth muscle cells following perfusion loading of Fura-2/AM in arterial segments.Cell Calcium1995;18:420-8

[33] Reger TS,Schlegel KA.Pyridyl amides as potent inhibitors of T-type calcium channels.Bioorg Med Chem Lett2011;21:1692-6

[34] Kumari N,Kumar P.Antagonistic interaction between TTA-A2 and paclitaxel for anti-cancer effects by complex formation with T-type calcium channel.J Biomol Struct Dyn2020;:1-12

[35] Dziegielewska B,Dziegielewski J.T-type calcium channels blockers as new tools in cancer therapies.Pflugers Arch2014;466:801-10

[36] Keir ST,Reardon DA,Gray LA.Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.J Neurooncol2013;111:97-102

[37] Eiro N,Martínez-Ordoñez A.Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis.Cell Oncol (Dordr)2018;41:369-78

[38] O'Reilly D.Calcium channels and cancer stem cells.Cell Calcium2019;81:21-8